Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | AR | P10275 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11455457 | 1.00 | RAB9A (0.75) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL11466217 | 0.93 | KDM4E (0.86) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL11213828 | 0.91 | SREBF2 (0.82) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL11215130 | 0.91 | SREBF2 (0.82) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL11212983 | 0.91 | SREBF2 (0.82) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL19196716 | 0.89 | CYP19A1 (0.61) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL11464717 | 0.89 | SREBF2 (0.79) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL2781370 | 0.89 | KDM4E (0.85) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL4283884 | 0.86 | KDM4E (1.00) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 | |
| SCHEMBL5647626 | 0.84 | KDM4E (0.73) | RAB9AKDM4ESMN1; SMN2LMNASREBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303213-A1 | Compositions and Methods for the Treatment of Metabolic Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-10-09 | — | — | US | claimed |
| CN-101674730-A | The composition and the method that are used for the treatment of metabolic disease | BAYLOR COLLEGE MEDICINE | 2010-03-17 | — | — | CN | claimed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | claimed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | claimed |
| WO-1998025918-A1 | ANALGESIC, ANTI-INFLAMMATORY AND ANTI-THROMBOSIS ESTERS OF NITRATED CYCLOALIPHATIC ALCOHOLS | HOECHST MARION ROUSSEL (FR) | 1998-06-18 | — | — | WO | claimed |
| CN-110627739-B | Method for synthesizing thiazole heterocyclic compound through photocatalysis | 桂林医学院 | 2023-02-07 | — | — | CN | disclosed |
| CN-111909110-A | Preparation method of 2, 4-disubstituted thiazole compound | 浙江工业大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-110627739-A | Method for synthesizing thiazole heterocyclic compound through photocatalysis | 桂林医学院 | 2019-12-31 | — | — | CN | disclosed |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2018-10-11 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | disclosed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | disclosed |
| CN-101674730-A | The composition and the method that are used for the treatment of metabolic disease | BAYLOR COLLEGE MEDICINE | 2010-03-17 | — | — | CN | disclosed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007062222-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-1998025918-A1 | ANALGESIC, ANTI-INFLAMMATORY AND ANTI-THROMBOSIS ESTERS OF NITRATED CYCLOALIPHATIC ALCOHOLS | HOECHST MARION ROUSSEL (FR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | HCCS, PCNA, MKI67 | RAB9A 3982/4885KDM4E 2557/4885SMN1; SMN2 2848/4885 |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | FABP4, LIPC, PNLIP | RAB9A 3100/4885KDM4E 2808/4885SMN1; SMN2 3787/4885 |
| US-20140303213-A1 | Compositions and Methods for the Treatment of Metabolic Disorders | FABP4, LIPC, PNLIP | RAB9A 3332/4885KDM4E 2584/4885SMN1; SMN2 3753/4885 |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | RAB9A 3385/4885KDM4E 2849/4885SMN1; SMN2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.